Preclinical evaluation and pilot clinical study of [68Ga]Ga-THP-APN09, a novel PD-L1 targeted nanobody radiotracer for rapid one-step radiolabeling and PET imaging
European Journal of Nuclear Medicine and Molecular Imaging · 2023-11 · 50 (13) · 3838-3850
DOI: 10.1007/s00259-023-06373-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 09.08.2023. Verfasst von Xiaopan Ma und 17 weiteren Autor:innen. Beteiligte Einrichtung: Medical College, Guizhou University, Guiyang, 550025, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Capital's Funds for Health Improvement and Research, Project of High-level Teachers in Beijing Municipal Universities in the Period of 13th Five-year Plan.
Abstract (Originalsprache)
PURPOSE: Programmed cell death protein-1/ligand-1 (PD-1/L1) blockade has been a breakthrough in the treatment of patients with non-small cell lung cancer (NSCLC), but there is still a lack of effective methods to screen patients. Here we report a novel 68 Ga-labeled nanobody [68 Ga]Ga-THP-APN09 for PET imaging of PD-L1 status in mouse models and a first-in-human study in NSCLC patients. METHODS: [68 Ga]Ga-THP-APN09 was prepared by site-specific radiolabeling, with no further purification. Cell uptake assays were completed in the human lung adenocarcinoma cell line A549, NSCLC cell line H1975 and human PD-L1 gene-transfected A549 cells (A549PD-L1). The imaging to image PD-L1 status and biodistribution were investigated in tumor-bearing mice of these three tumor cell types. The first-in-human clinical translational trial was registered as NCT05156515. The safety, radiation dosimetry, biodistribution, and correlations of tracer uptake with immunohistochemical staining and major pathologic response (MPR) were evaluated in NSCLC patients who underwent adjuvant immunotherapy combined with chemotherapy. RESULTS: Radiosynthesis of [68 Ga]Ga-THP-APN09 was achieved at room temperature and a pH of 6.0-6.5 in 10 min with a high radiochemical yield (> 99%) and 13.9-27.8 GBq/μmol molar activity. The results of the cell uptake study reflected variable levels of surface PD-L1 expression observed by flow cytometry in the order A549PD-L1 > H1975 > A549. In small-animal PET/CT imaging, H1975 and A549PD-L1 tumors were clearly visualized in an 8.3:1 and 2.2:1 ratios over PD-L1-negative A549 tumors. Ex vivo biodistribution studies showed that tumor uptake was consistent with the PET results, with the highest A549PD-L1 being taken up the most (8.20 ± 0.87%ID/g), followed by H1975 (3.69 ± 0.50%ID/g) and A549 (0.90 ± 0.16%ID/g). Nine resectable NSCLC patients were enrolled in the clinical study. Uptake of [68 Ga]Ga-THP-APN09 was mainly observed in the kidneys and spleen, followed by low uptake in bone marrow. The radiation dose is within a reliable range. Tumor uptake was positively correlated with PD-L1 expression TPS (rs = 0.8763, P = 0.019). Tumor uptake of [68 Ga]Ga-THP-APN09 (SUVmax) in MPR patients was higher than that in non-MPR patients (median SUVmax 2.73 vs. 2.10, P = 0.036, determined with Mann-Whitney U-test). CONCLUSION: [68 Ga]Ga-THP-APN09 has the potential to be transformed into a kit-based radiotracer for rapid, simple, one-step, room temperature radiolabeling. The tracer can detect PD-L1 expression levels in tumors, and it may make it possibility to predict the response of PD-1 immunotherapy combined with chemotherapy. Confirmation in a large number of cases is needed. TRIAL REGISTRATION: Clinical Trial (NCT05156515). Registered 12 December 2021.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical College, Guizhou University, Guiyang, 550025, China.
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of N…
- Medical Isotopes Research Center and Department of Radiation Medicine, School of Basic Medical Sciences, Peking University, No.38 Xueyuan Rd., Beijing, 100191, China.
- Department of Nuclear Medicine, Molecular Imaging Lab, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
- Medical Isotopes Research Center and Department of Radiation Medicine, School of Basic Medical Sciences, Peking University, No.38 Xueyuan Rd., Beijing, 100191, China. jiabing@bjmu.edu.cn.
ORCID-Profile: Zhi Yang
Förderung
- National Natural Science Foundation of China
- Capital's Funds for Health Improvement and Research
- Project of High-level Teachers in Beijing Municipal Universities in the Period of 13th Five-year Plan
- Digestive Medical Coordinated Development Center of Beijing Hospitals Authority
- Capital’s Funds for Health Improvement and Research
Zitieren
APA
Ma, X., Zhou, X., Hu, B., Li, X., Yao, M., Li, L., Qin, X., Li, D., Yao, Y., Hou, X., Liu, S., Chen, Y., Wang, Z., Zhou, W., Li, N., Zhu, H., Jia, B., & Yang, Z. (2023). Preclinical evaluation and pilot clinical study of [68Ga]Ga-THP-APN09, a novel PD-L1 targeted nanobody radiotracer for rapid one-step radiolabeling and PET imaging. European Journal of Nuclear Medicine and Molecular Imaging, 50(13), 3838-3850. https://doi.org/10.1007/s00259-023-06373-3
Vancouver
Ma X, Zhou X, Hu B, Li X, Yao M, Li L, et al. Preclinical evaluation and pilot clinical study of [68Ga]Ga-THP-APN09, a novel PD-L1 targeted nanobody radiotracer for rapid one-step radiolabeling and PET imaging. European Journal of Nuclear Medicine and Molecular Imaging. 2023;50(13):3838-3850. doi:10.1007/s00259-023-06373-3
BibTeX
@article{Ma2023,
author = {Ma, Xiaopan and Zhou, Xin and Hu, Biao and Li, Xiaoda and Yao, Meinan and Li, Liqiang and Qin, Xue and Li, DaPeng and Yao, Yuan and Hou, Xingguo and Liu, Song and Chen, Yan and Wang, Zilei and Zhou, Wenyuan and Li, Nan and Zhu, Hua and Jia, Bing and Yang, Zhi},
title = {Preclinical evaluation and pilot clinical study of [68Ga]Ga-THP-APN09, a novel PD-L1 targeted nanobody radiotracer for rapid one-step radiolabeling and PET imaging},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2023},
volume = {50},
number = {13},
pages = {3838--3850},
doi = {10.1007/s00259-023-06373-3}
}
EUVIMED